'김갑성' 기자의 전체기사
-
Strider Technologies、NATOの防衛イノベーション・アクセラレーターとの…
NATO DIANAは、Striderの戦略的情報を経済安全保障ツールとして活用 ロンドン, 2025年9月11日 -- 戦略インテリジェンスの大手プロバイダーであるStrider Technologies, Inc.は本日、NATOの北大西洋防衛イノベーション・アクセラレーター（Defence Innovation Accelerator for the North Atlantic、DIANA）との新たなパートナーシップを発表しました。 このパートナーシップに基づき、Striderは経済安全保障機能を提供し、NATO 2022戦略コンセプト（NATO 2022 Strategic Concept）に定められた戦略的競争相手からの契約およびサプライ・チェーンのリスクを特定するためにNATO DIANAを支援します。 Striderの戦略的インテリジェンスは、DIANA防衛イノベーション・エコシステムに参加して協力したい組織や個人からのリスクを評価するためにも使用されます。 「NATOの北大西洋防衛イノベーション・アクセラレーター（Defence Innovation Accelerator for the North Atlantic）は、同盟の安全保障に不可欠な貢献をするイノベーター、起業家、メンターのダイナミックなエコシステムを構
- 김갑성 기자
- 2025-09-11 20:36
-
GLOBAL FIRST "High-Definition Image": Decoding the "Code of…
CHENGDU, China, Sept. 11, 2025 -- Recently, LivingPhoenix®Regenerative Technologies Development (Chengdu) Co., Ltd., announced that its self-developed POGMENT triple-helix biomimetic collagen has, for the first time globally, achieved high-resolution molecular visualization of "collagen fiber bundles" using Cryo-Electron microscopy (Cryo-EM) under near-physiological and cryogenic conditions. This breakthrough fills the international knowledge gap in understanding collagen's self-assembly mechanism. The result was achieved through collaboration with the Cryo-EM platform te
- 김갑성 기자
- 2025-09-11 20:26
-
YolTech Therapeutics Raises $45 Million in Series B Financ…
SHANGHAI, Sept. 11, 2025 -- YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately $45 million Series B financing led by the AstraZeneca-CICC healthcare investment fund. The proceeds will support the advancement of YolTech's clinical programs and global strategic execution. Dr. Yuxuan Wu, Founder and CEO of YolTech, "This financing marks an important milestone as we continue advancing our pipeline toward transformative therapies. We are committed to turning cutting-edge gene-editing scien
- 김갑성 기자
- 2025-09-11 20:05
-
Kazia Therapeutics Reports Complete Ex Vivo Disruption of L…
SYDNEY, Sept. 11, 2025 -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led by Professor Sudha Rao at QIMR Berghofer. In this ex vivo study, blood samples from Stage IV HER2-positive metastatic breast cancer (mBC) patients were profiled to evaluate the effect of paxalisib, Kazia's investigational PI3K–mTOR inhibitor, on metastatic burden. Paxalisib monotherapy demonstrated a statistically significant reduction in single circulating tumor cells and achieved a complete (100%) dis
- 김갑성 기자
- 2025-09-11 20:00
-
Lundbeck showcases new clinical migraine data, includi…
[ 메디채널 김갑성 기자 ] Lundbeck demonstrates leadership and unwavering commitment to advancing migraine management and supporting patient outcomes with six presentations at the 2025 International Headache Congress (IHC), including three oral presentations on eptinezumab (Vypeti®) and Lu AG09222 (anti-PACAP mAb) New data from the open-label extension of the RESOLUTION trial and the primary results of the SUNSET extension trial will be presented for the first time at IHC1,2 Patients treated with eptinezumab experienced sustained reductions in migraine symptom and burden, including long-term r
- 김갑성 기자
- 2025-09-11 14:56
-
HaemaLogiX wins "Most Promising CAR-T Pipeline in APAC" at th…
SYDNEY, Sept. 11, 2025 -- HaemaLogiX Ltd, a clinical stage Australian biotech, developing novel immunotherapies for patients with blood cancers and B-cell diseases, was honoured to be awarded the "Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT Excellence Awards 2025, held in Singapore last night. The award recognises companies demonstrating outstanding innovation, scientific excellence, and translational potential in the rapidly evolving CAR T therapy sector. This accolade highlights HaemaLogiX's role as a leader in advancing CAR T-cell therapies that
- 김갑성 기자
- 2025-09-11 11:52
-
Amaran Biotech Wins Asia-Pacific Biologics CDMO Excellence…
[ 메디채널 김갑성 기자 ] 50-Person Team Demonstrates Taiwan's Biotech Strength HSINCHU, Sept. 11, 2025 -- Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), was awarded the "Best Fill-Finish" at the 2025 Asia-Pacific Biologics CDMO Excellence Awards held in Singapore on September 10. This honor recognizes Amaran Biotech's leading capabilities in aseptic fill-finish processes and marks an important step for Taiwan's biotech industry on the international stage. The Asia-Pacific Biologics CDMO Excellence Awards, organized by the renowne
- 김갑성 기자
- 2025-09-11 10:00
-
SynbioTech's TWK10 Approved to Boost Muscle Strength, Th…
BANGKOK, Sept. 11, 2025 -- SynbioTech Inc., ranked among the world's top 20 probiotic suppliers, is the leader in functional probiotics for muscle and joint health, sports, women's wellness, and immune support. Its patented flagship probiotic, Lactiplantibacillus plantarum TWK10®, has earned multiple awards in Europe, the US and Japan, with clinical trials showing increased muscle mass and reduced body fat. In 2024, TWK10® was approved by the Thai government as an edible strain, making it a key focus in the Thai market. SynbioTech will showcase this and other flagship probiotics at Vi
- 김갑성 기자
- 2025-09-11 10:00
-
Allianz Partners appoints Okan Özdemir as its new Chief Offic…
BRISBANE, Australia, Sept. 11, 2025 -- Allianz Partners, a global leader in insurance and assistance services, is pleased to announce the appointment of Okan Özdemir as its new Chief Officer for Health and Board Member, effective September 1, 2025. In this role, Okan will report directly to Allianz Partners CEO Tomas Kunzmann. Okan Özdemir joins Allianz Partners from Allianz Türkiye, where he served as Chief Health Officer and Executive Board Member since 2019. With over 24 years of strong leadership at Allianz in a number of strategic roles including Ch
- 김갑성 기자
- 2025-09-11 07:00
-
XingImaging in partnership with SynuSight was awarded a gr…
NEW HAVEN, Conn., Sept. 11, 2025 -- XingImaging in partnership with SynuSight Biotech has received funding of $3.84M from The Michael J. Fox Foundation to conduct studies on 18F-FD4, a specific α-synuclein (α-syn)-targeted PET tracer. Based on prior investigator-initiated trials, the SynuSight Biotech developed technology, showed the potential to become the world's first α-syn-targeted PET tracer for Parkinson's disease (PD), multiple system atrophy (MSA), and rapid eye movement sleep behavior disorder (RBD). XingImaging is a leading neuroimaging and radiopharmaceutical service
- 김갑성 기자
- 2025-09-11 05:06
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-22_WED
2025-10-21_TUE
- AESOP Technology announces DxPrime is now a qualified solution on Mayo Clinic Platform 23:30
- Charming Medical Limited Announces Pricing of Initial Public Offering and Listing on Nasdaq 23:00
- Stéphane Rolland's Haute Couture to Illuminate the 10th Anniversary of Barcelona Bridal Night 23:00
- JOY GROUP Completes Acquisition of Italian Dermatological Hair Care Brand Foltène 22:00
- AI meets capital: Bizcap welcomes 8fig into its global portfolio to accelerate growth funding 22:00
- Youth Innovation Safeguards Green Heritage: 2025 World Food Forum Youth Action on Green Agri-Heritage Held in Rome 21:00
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 22일 03시 00분